Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693054 | 0.79 | TNF (0.35) | TNFRIPK1 | |
| SCHEMBL2046247 | 0.77 | TNF (0.41) | TNFRIPK1CES2CES1 | |
| SCHEMBL31289362 | 0.77 | TNF (0.41) | TNFRIPK1CES2CES1 | |
| SCHEMBL489680 | 0.75 | CES2 (0.40) | CES2CES1 | |
| SCHEMBL487703 | 0.73 | LMNA (0.33) | — | |
| SCHEMBL3960570 | 0.72 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL1756509 | 0.72 | CYP3A4 (0.38) | TNFRIPK1CES2CES1 | |
| Nitrogen SCHEMBL28690307 | 0.70 | TNF (0.37) | TNFRIPK1CES2CES1 | |
| SCHEMBL18709780 | 0.70 | NOTUM (0.43) | TNFRIPK1CES2CES1 | |
| SCHEMBL3066742 | 0.70 | PTPN11 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363421-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-05-08 | — | — | EP | disclosed |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2024-05-02 | — | — | US | disclosed |
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-12-14 | — | — | US | disclosed |
| EP-4259631-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-10-18 | — | — | EP | disclosed |
| EP-4240742-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-08-31 | — | — | US | disclosed |
| EP-4132650-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023275301-A1 | IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-01-05 | — | — | WO | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-07-21 | — | — | US | disclosed |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | US | disclosed |
| WO-2020260426-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020260425-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020261141-A1 | IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| EP-3740478-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-11-25 | — | — | EP | disclosed |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | UCB Biopharma SRL (BE) | 2020-05-07 | — | — | US | disclosed |
| EP-3638227-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018229079-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | WO | disclosed |
| WO-2011161615-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399328-A1 | DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL23R, IL2 | TNF 143/4885RIPK1 307/4885CES2 4185/4885 |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | TNF 91/4885RIPK1 457/4885CES2 4737/4885 |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | TNF 80/4885RIPK1 705/4885CES2 4793/4885 |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL2, IL23R | TNF 67/4885RIPK1 1847/4885CES2 4240/4885 |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | IL17A, IL2, IL18 | TNF 131/4885RIPK1 362/4885CES2 4647/4885 |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | IL17A, IL2, IL18 | TNF 131/4885RIPK1 362/4885CES2 4647/4885 |
| US-20240140951-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS | IL17A, IL15, IL2 | TNF 146/4885RIPK1 1315/4885CES2 4530/4885 |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | TNF 91/4885RIPK1 457/4885CES2 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.